Entheon Biomedical Corp. provide an update on its Observational Study, EBIQ-101. The results of EBIQ-101 will serve as the foundation for the strategic aims of Entheon IQTM and Entheon IDTM, the development of a framework for characterizing the psychedelic drug state of patients, and to research phenotypes associated with particular addictions and mental health disorders.